CMPS250117C2500
- 0.98
- 0.000.00%
COMPASS Pathways Newsroom
Compass Pathways Appoints Steve Levine as Chief Patient Officer
RBC Capital Reiterates Outperform on Compass Pathways, Maintains $18 Price Target
Compass Pathways Analyst Ratings
RBC Capital Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $18
Psychedelic Drug Developer Lykos Could Get Lifeline From Former Tesla Board Member
Compass Pathways Prices Offering of American Depositary Shares, Pre-Funded Warrants
COMPASS Pathways Boosts Funds for Mental Health Trials
Express News | Compass Pathways PLC - Offering Price Is $4.275 per Ads and Accompanying Ads Warrant
Express News | Compass Pathways Announces Pricing of Underwritten Offering
Recent Uptick Might Appease COMPASS Pathways Plc (NASDAQ:CMPS) Institutional Owners After Losing 52% Over the Past Year
Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index
Earnings Week Ahead: FDX, NKE, CCL, BB, ACN, MU, and More
Compass Pathways to Participate in December Investor Conferences
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
Express News | GH Research Shares up 4.1%
Express News | Compass Pathways Shares up 11.9%
Express News | Shares of Psychedelic Drug Developers Rise After Rfk Jr Picked for Top US Health Agency Role